About this episode
New medicines with sales in the billions of dollars each year are what every pharmaceutical company dreams of, but how do you create one and can they really justify their often high price tags?
Evan Davis and guests discuss the changing origins of so-called 'blockbusters' and their importance to the global drug industry, including recent examples like the obesity and diabetes treatments Wegovy and Ozempic, which have made Novo Nordisk one of the richest companies in Europe.
Plus, as outright cures for some diseases begin to emerge, how can the pharmaceutical industry and healthcare systems agree on what is a reasonable price to pay for them?
Evan is joined by:
Sir Patrick Vallance, former president of research and development at GSK, chief scientific advisor to the UK government, now chair of the Natural History Museum; Ruth McKernan, venture partner at SV Health Investors; David Brown, chairman and co-founder of Healx and co-creator of Viagra; Natasha Loder, health editor, The Economist.
PRODUCTION TEAM:
Producer: Simon Tulett Editor: China Collins Sound: Graham Puddifoot Production co-ordinator: Gemma Ashman
(Picture: Rolls of dollar bills next to a bottle of pills. Credit: Getty Images)
Get every episode summarized
Each time The Bottom Line publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
